International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

NCT02724163

Last updated date
Study Location
Royal Aberdeen Children's Hospital
Aberdeen, , AB25 2ZG, United Kingdom
Contact
01214151049

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

01214151049

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myeloid Leukaemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-17
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Inclusion criteria for trial entry and R1 randomisation.

- Diagnosis of acute myeloid leukaemia (AML) /high risk Myelodysplastic syndrome (MDS) (>10% blasts in the bone marrow)/isolated myeloid sarcoma (MS) (either de novo or secondary).

- Age <18 years.

- No prior chemotherapy or biological therapy for AML other than that permitted in the protocol.

- Normal cardiac function defined as fractional shortening ≥28% or ejection fraction ≥55%.

- Fit for protocol chemotherapy.

- Documented negative pregnancy test for female patients of childbearing potential.

- Patient agrees to use effective contraception (patients of child bearing potential).

- Written informed consent from the patient and/or parent/legal guardian.

Inclusion criteria for participation in the gemtuzumab ozogamicin dose finding study:

Centres must be formally activated in order to be take part in the embedded dose escalation study. Please contact the trial office for further information.

- Patient meets the inclusion criteria for trial entry.

- Age:

- ≥12 months for the major dose finding study

- ≥ 12 weeks and <12 months for the minor dose finding study

- Karnofsky or Lansky performance score of ≥50.

- Normal renal function defined as calculated creatinine clearance ≥90ml/min/1.73m2.

- Normal hepatic function defined as total bilirubin ≤2.5 upper limit of normal (ULN) for age unless it is caused by leukaemic involvement or Gilbert's syndrome or similar disorder.

- Alanine transaminase (ALT) or aspartate transaminase (AST) ≤10 x ULN for age.

- Written informed consent from the patient and/or parent/legal guardian.

Inclusion criteria for participation in R2 (randomisation not yet open).

- Patient meets the inclusion criteria for trial entry

- Age ≥12 weeks.

- Karnofsky or Lansky performance score of ≥50.

- Normal renal function defined as calculated creatinine clearance ≥90ml/min/1.73m2.

- Normal hepatic function defined as total bilirubin ≤2.5 ULN for age and not due to leukaemic involvement or Gilbert's syndrome or similar disorder.

- ALT or AST ≤10 x ULN for age.

- Written informed consent from the patient and/or parent/legal guardian.

Inclusion criteria for participation in R3.

- Patient meets the inclusion criteria for trial entry

- Induction treatment as per MyeChild 01 protocol or treated with 2 courses of mitoxantrone & cytarabine off trial.

- Minimal residual disease (MRD) response (performed in MyeChild 01 centralised laboratories, see national MyeChild 01 Laboratory Manual):

- Patients with good risk cytogenetics/molecular genetics and a MRD level <0.1% by flow after course 2, or a decrease in transcript levels of >3 logs after course 2 for those with an informative molecular marker, but without an informative marker of sufficient sensitivity for flow MRD monitoring or

- Patients with intermediate risk cytogenetics/molecular genetics with a MRD level <0.1% by flow after course 1 and course 2, or a decrease in transcript levels of >3 logs after course 1 and course 2 for those with an informative molecular marker, but without an informative marker of sufficient sensitivity for flow MRD monitoring.

- Written informed consent from the patient and/or parent/legal guardian.

Inclusion criteria for participation in R4.

- Patient meets the inclusion criteria for trial entry

- Induction treatment as per MyeChild 01 protocol or treated with 1 or 2 courses of mitoxantrone & cytarabine ± treatment intensification with fludarabine, cytarabine & idarubicin (FLA-Ida) off trial.

- Patient is in complete remission (CR) or CR with incomplete blood count recovery (CRi) defined as <5% blasts confirmed by flow cytometry/ molecular/FISH in a bone marrow aspirate taken within 6 weeks prior to randomisation to R4.

- Patient meets one of the following criteria and is a candidate for HSCT as per the protocol:

- High risk after course 1 (all patients with poor risk cytogenetics and patients with intermediate risk cytogenetics who fail to achieve CR/CRi).

- Intermediate risk cytogenetics with MRD >0.1% after course 1 and 2 measured by flow. If no flow MRD marker of sufficient sensitivity is identified, a molecular MRD marker with a sensitivity of >0.1% may be used.

- Good risk cytogenetics with flow MRD >0.1% confirmed by a decrease in molecular MRD of <3 logs or rising transcript levels after course 3 despite treatment intensification (FLA-Ida) and after discussion with the Clinical Co-ordinators.

- Availability of a 9-10/10 human leukocyte antigen (HLA) matched family or unrelated donor or 5-8/8 matched cord blood unit with an adequate cell dose as defined by the protocol section 17.1.

- Written informed consent from the patient and/or parent/legal guardian.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Exclusion criteria for all randomisations


- Acute Promyelocytic Leukaemia.


- Myeloid Leukaemia of Down Syndrome.


- Blast crisis of chronic myeloid leukaemia.


- Relapsed or refractory AML.


- Bone marrow failure syndromes.


- Prior anthracycline exposure which would inhibit the delivery of study anthracyclines.


- Concurrent treatment or administration of any other experimental drug or with any
other biological therapy for AML.


- Pregnant or lactating females.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Myeloid LeukaemiaInternational Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
NCT02724163
  1. Aberdeen,
  2. Aberdeen,
  3. Birmingham,
  4. Bristol,
  5. Cambridge,
  6. Cardiff,
  7. Edinburgh,
  8. Glasgow,
  9. Leeds,
  10. Liverpool,
  11. London,
  12. London,
  13. London,
  14. Manchester,
  15. Manchester,
  16. Newcastle,
  17. Nottingham,
  18. Oxford,
  19. Sheffield,
  20. Southampton,
  21. Belfast,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Official Title  ICMJE International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy
Brief Summary

The main purpose of this study is :

  1. To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or liposomal daunorubicin in induction
  2. To compare mitoxantrone (anthracenedione) & cytarabine with liposomal daunorubicin (anthracycline) & cytarabine as induction therapy.
  3. To compare a single dose of gemtuzumab ozogamicin with the optimum tolerated number of doses of gemtuzumab ozogamicin (identified by the dose-finding study) when combined with induction chemotherapy.
  4. To compare two consolidation regimens: high dose cytarabine (HD Ara-C) and fludarabine & cytarabine (FLA) in standard risk patients.
  5. To compare the toxicity and effectiveness of two haemopoietic stem cell transplant (HSCT) conditioning regimens of different intensity: conventional myeloablative conditioning (MAC) with busulfan/cyclophosphamide and reduced intensity conditioning (RIC) with fludarabine/busulfan.
Detailed Description MyeChild 01 is an international phase III clinical trial in children with acute myeloid leukaemia (AML)? a disease with significant mortality. It will compare two induction chemotherapy regimens: mitoxantrone and cytarabine (current standard treatment) with liposomal daunorubicin and cytarabine. This will test liposomal daunorubicin, which is believed to be less cardiotoxic than similar conventional drugs, although this is unproven. Patients responding well to induction chemotherapy are eligible for a randomisation of two consolidation regimens: high dose cytarabine (current standard treatment) or fludarabine and cytarabine (FLA)? a regimen commonly used in patients with relapsed disease, testing whether FLA is more effective in front line therapy than standard consolidation treatment. Patients with cytogenetic features associated with a higher risk of relapse and those responding sub-optimally to induction treatment are candidates for haemopoietic stem cell transplant (HSCT) and are eligible for a randomisation comparing two HSCT conditioning regimens: myeloablative conditioning (MAC) (current UNited Kingdom (UK) standard) or reduced intensity conditioning (RIC). HSCT has not consistently shown benefit in high risk patients because the mortality associated with the procedure has outweighed the advantage from a reduction in relapse risk. This will test whether reducing the intensity of conditioning improves survival by reducing transplant related deaths without increasing the relapse rate. The trial incorporates a dose finding study for gemtuzumab ozogamicin. The aim is to identify the optimum tolerated number of doses of gemtuzumab ozogamicin (up to a total of 3 doses), which can be safely combined with either of the induction chemotherapy regimens and then to compare this number of doses with one dose of gemtuzumab ozogamicin. The intensity of treatment will be directed by cytogenetics/molecular genetics and response assessed by minimal residual disease (MRD) levels measured by flow cytometry and molecular methodology.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Acute Myeloid Leukaemia
Intervention  ICMJE
  • Drug: Gemtuzumab ozogamicin
    Antibody-conjugated chemotherapy agent.
    Other Name: Mylotarg
  • Drug: Liposomal daunorubicin
    Anthracycline
  • Drug: Mitoxantrone
    DNA-reactive agent
  • Drug: Fludarabine
    A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
  • Drug: Cytarabine
    Pyrimidine nucleoside analogue, an antineoplastic agent.
  • Drug: Busulfan
    Alkylsulfonate
  • Drug: Cyclophosphamide
    A nitrogen mustard alkylating agent from the oxazaphosphorine group
Study Arms  ICMJE
  • Active Comparator: Mitoxantrone

    Course 1

    • Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2, 3 and 4 (total 4 doses).
    • Cytarabine:100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).

    Course 2

    • Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2 and 3 (total 3 doses).
    • Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses).
    Interventions:
    • Drug: Mitoxantrone
    • Drug: Cytarabine
  • Experimental: Liposomal daunorubicin

    Course 1

    • Liposomal daunorubicin: 80 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).
    • Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).

    Course 2

    • Liposomal daunorubicin: 60 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).
    • Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses).
    Interventions:
    • Drug: Liposomal daunorubicin
    • Drug: Cytarabine
  • Experimental: Gemtuzumab Ozogamicin Dose Finding Study
    • Cohort 1: 1x3mg/m2 IV infusion over 2hours on day 4.
    • Cohort 2: 2x3mg/m2 IV infusion over 2hours on day 4 and day 7.
    • Cohort 3: 3x3mg/m2 IV infusion over 2hours on days 4, 7 and 10.
    Intervention: Drug: Gemtuzumab ozogamicin
  • Active Comparator: High dose cytarabine
    Two courses of Cytarabine: 3 g/m2 12 hourly by IV infusion over 4 hours on days 1, 3 and 5 (total 6 doses).
    Intervention: Drug: Cytarabine
  • Experimental: Fludarabine & cytarabine

    Two courses of:

    • Fludarabine: 30 mg/m2 daily by IV infusion over 30 minutes on days 1-5 inclusive (total 5 doses).
    • Cytarabine: 2 g/m2 daily by IV infusion over 4 hours on days 1-5 inclusive (total 5 doses).The cytarabine infusion should be started 4 hours after the start of the fludarabine infusion
    Interventions:
    • Drug: Fludarabine
    • Drug: Cytarabine
  • Active Comparator: Myeloablative conditioning
    • Busulfan Area Under the Curve (AUC) 70-100mg/L x hr by IV infusion over 3 hours, given 12 hourly on days -10 to -7 (8 doses).
    • Cyclophosphamide 50mg/kg/day by IV infusion over 1 hour, on days -5 to -2 (4 doses).
    Interventions:
    • Drug: Busulfan
    • Drug: Cyclophosphamide
  • Experimental: Reduced intensity conditioning
    • Busulfan AUC60-65mg/L X hr by IV infusion over 3 hours, given 12 hourly on days -5 to -2 (8 doses).
    • Fludarabine 30mg/m2/day by IV infusion over 30 minutes on days -8 to -3 (6 doses).
    Interventions:
    • Drug: Fludarabine
    • Drug: Busulfan
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 24, 2016)
700
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2032
Estimated Primary Completion Date December 2031   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Inclusion criteria for trial entry and R1 randomisation.

  • Diagnosis of acute myeloid leukaemia (AML) /high risk Myelodysplastic syndrome (MDS) (>10% blasts in the bone marrow)/isolated myeloid sarcoma (MS) (either de novo or secondary).
  • Age <18 years.
  • No prior chemotherapy or biological therapy for AML other than that permitted in the protocol.
  • Normal cardiac function defined as fractional shortening ?28% or ejection fraction ?55%.
  • Fit for protocol chemotherapy.
  • Documented negative pregnancy test for female patients of childbearing potential.
  • Patient agrees to use effective contraception (patients of child bearing potential).
  • Written informed consent from the patient and/or parent/legal guardian.

Inclusion criteria for participation in the gemtuzumab ozogamicin dose finding study:

Centres must be formally activated in order to be take part in the embedded dose escalation study. Please contact the trial office for further information.

  • Patient meets the inclusion criteria for trial entry.
  • Age:

    • ?12 months for the major dose finding study
    • ? 12 weeks and <12 months for the minor dose finding study
  • Karnofsky or Lansky performance score of ?50.
  • Normal renal function defined as calculated creatinine clearance ?90ml/min/1.73m2.
  • Normal hepatic function defined as total bilirubin ?2.5 upper limit of normal (ULN) for age unless it is caused by leukaemic involvement or Gilbert's syndrome or similar disorder.
  • Alanine transaminase (ALT) or aspartate transaminase (AST) ?10 x ULN for age.
  • Written informed consent from the patient and/or parent/legal guardian.

Inclusion criteria for participation in R2 (randomisation not yet open).

  • Patient meets the inclusion criteria for trial entry
  • Age ?12 weeks.
  • Karnofsky or Lansky performance score of ?50.
  • Normal renal function defined as calculated creatinine clearance ?90ml/min/1.73m2.
  • Normal hepatic function defined as total bilirubin ?2.5 ULN for age and not due to leukaemic involvement or Gilbert's syndrome or similar disorder.
  • ALT or AST ?10 x ULN for age.
  • Written informed consent from the patient and/or parent/legal guardian.

Inclusion criteria for participation in R3.

  • Patient meets the inclusion criteria for trial entry
  • Induction treatment as per MyeChild 01 protocol or treated with 2 courses of mitoxantrone & cytarabine off trial.
  • Minimal residual disease (MRD) response (performed in MyeChild 01 centralised laboratories, see national MyeChild 01 Laboratory Manual):

    • Patients with good risk cytogenetics/molecular genetics and a MRD level <0.1% by flow after course 2, or a decrease in transcript levels of >3 logs after course 2 for those with an informative molecular marker, but without an informative marker of sufficient sensitivity for flow MRD monitoring or
    • Patients with intermediate risk cytogenetics/molecular genetics with a MRD level <0.1% by flow after course 1 and course 2, or a decrease in transcript levels of >3 logs after course 1 and course 2 for those with an informative molecular marker, but without an informative marker of sufficient sensitivity for flow MRD monitoring.
  • Written informed consent from the patient and/or parent/legal guardian.

Inclusion criteria for participation in R4.

  • Patient meets the inclusion criteria for trial entry
  • Induction treatment as per MyeChild 01 protocol or treated with 1 or 2 courses of mitoxantrone & cytarabine ± treatment intensification with fludarabine, cytarabine & idarubicin (FLA-Ida) off trial.
  • Patient is in complete remission (CR) or CR with incomplete blood count recovery (CRi) defined as <5% blasts confirmed by flow cytometry/ molecular/FISH in a bone marrow aspirate taken within 6 weeks prior to randomisation to R4.
  • Patient meets one of the following criteria and is a candidate for HSCT as per the protocol:

    • High risk after course 1 (all patients with poor risk cytogenetics and patients with intermediate risk cytogenetics who fail to achieve CR/CRi).
    • Intermediate risk cytogenetics with MRD >0.1% after course 1 and 2 measured by flow. If no flow MRD marker of sufficient sensitivity is identified, a molecular MRD marker with a sensitivity of >0.1% may be used.
    • Good risk cytogenetics with flow MRD >0.1% confirmed by a decrease in molecular MRD of <3 logs or rising transcript levels after course 3 despite treatment intensification (FLA-Ida) and after discussion with the Clinical Co-ordinators.
  • Availability of a 9-10/10 human leukocyte antigen (HLA) matched family or unrelated donor or 5-8/8 matched cord blood unit with an adequate cell dose as defined by the protocol section 17.1.
  • Written informed consent from the patient and/or parent/legal guardian.

Exclusion Criteria:

Exclusion criteria for all randomisations

  • Acute Promyelocytic Leukaemia.
  • Myeloid Leukaemia of Down Syndrome.
  • Blast crisis of chronic myeloid leukaemia.
  • Relapsed or refractory AML.
  • Bone marrow failure syndromes.
  • Prior anthracycline exposure which would inhibit the delivery of study anthracyclines.
  • Concurrent treatment or administration of any other experimental drug or with any other biological therapy for AML.
  • Pregnant or lactating females.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE up to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Christina Ryan01214151049[email protected]
Contact: Raj Athwal01214151068[email protected]
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02724163
Other Study ID Numbers  ICMJE RG_14-088
2014-005066-30 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party University of Birmingham
Study Sponsor  ICMJE University of Birmingham
Collaborators  ICMJE
  • Assistance Publique - Hôpitaux de Paris
  • Cancer Research UK
  • National Cancer Institute, France
  • Pfizer
Investigators  ICMJE
Principal Investigator:Brenda GibsonRoyal Hospital for Children Glasgow
PRS Account University of Birmingham
Verification Date May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP